论文部分内容阅读
采用全身化疗联合重组人白细胞介素-2（rhIL－2）瘤体内注射治疗肺癌18例。结果，治疗组Karnofsky体力活动状态（KPS）分级均提高2～3级，全身化疗后1～2周内外用血CD_3、CD_4提高，CD_8下降，总有效率83．3％，显著高于对照组（55．0％，P＜0．01）；治疗组与对照组有效中位缓解期分别为6个月和3个月，随访6～12月，治疗组均存活，对照组有5例死亡。说明rhIL－2具有特殊的药理作用，配合全身化疗是目前疗效较为确切的治疗模式。
Systemic chemotherapy combined with recombinant human interleukin-2 (rhIL-2) tumor injection in 18 patients with lung cancer. As a result, the Karnofsky physical activity status (KPS) grades in the treatment group increased by 2 to 3 grades, CD_3 and CD_4 increased within 1 to 2 weeks after systemic chemotherapy, CD_8 decreased, and the total effective rate was 83.3%, which was significantly higher than that of the control group. (55.0%, P<0.01); effective median remission was 6 months and 3 months in the treatment group and the control group, respectively, follow-up from 6 to 12 months, the treatment group survived, the control group had 5 deaths . It is indicated that rhIL-2 has special pharmacological effects. The systemic chemotherapy combined with it is currently the most effective treatment mode.